News NHS cleared to use Novo Nordisk's long-acting growth hormone Novo Nordisk's long-acting injectable Sogroya has been backed for NHS use in young people with growth hormone deficiency.
Partner Content Partner Content World Biosimilars Market will surge at 27%+ CAGR up to 2025 Biosimilars Market will surpass USD 69 billion by 2025
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
